PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31502400-0	2019	Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS).	cediranib	0-9	ASPSCR1 tether for SLC2A4, UBX domain containing	Homo sapiens	81-85	
31502400-3	2019	In a phase-II trial of the VEGF receptor inhibitor cediranib for adults with ASPS, the partial response (PR) rate (response evaluation criteria in solid tumors [RECIST] v1.0) was 35% (15/43; 95% confidence interval: 21-51%).	cediranib	51-60	ASPSCR1 tether for SLC2A4, UBX domain containing	Homo sapiens	77-81	
23630200-3	2013	PATIENTS AND METHODS: We conducted a phase II trial of once-daily cediranib (30 mg) given in 28-day cycles for patients with metastatic, unresectable ASPS to determine the objective response rate (ORR).	cediranib	66-75	ASPSCR1 tether for SLC2A4, UBX domain containing	Homo sapiens	150-154	
23630200-9	2013	CONCLUSION: In this largest prospective trial to date of systemic therapy for metastatic ASPS, we observed that cediranib has substantial single-agent activity, producing an ORR of 35% and a disease control rate of 84% at 24 weeks.	cediranib	112-121	ASPSCR1 tether for SLC2A4, UBX domain containing	Homo sapiens	89-93	
23630200-10	2013	On the basis of these results, an open-label, multicenter, randomized phase II registration trial is currently being conducted for patients with metastatic ASPS comparing cediranib with another VEGFR inhibitor, sunitinib.	cediranib	171-180	ASPSCR1 tether for SLC2A4, UBX domain containing	Homo sapiens	156-160